The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise $350M-plus on Nas­daq

2 days ago
IPOs
China

Macro­Gen­ics CEO Scott Koenig gets the pre-AS­CO par­ty start­ed with some en­cour­ag­ing pipeline tid­bits — leav­ing lots of ques­tions for lat­er

4 weeks ago
Bioregnum
R&D

Deal­mak­ing spiked to record lev­els in April as Covid-19 trig­gered a fever of part­ner­ing. But what hap­pens to col­lab­o­ra­tions in a new world seen through Zoom?

4 weeks ago
Deals

Full steam ahead, Pfiz­er goes bar­gain hunt­ing in an age of coro­n­avirus — with a spe­cial fo­cus on can­cer and rare dis­eases

Last month
Bioregnum
R&D

A slice of half-baked remde­sivir da­ta takes a dark turn — but we're still wait­ing for a de­fin­i­tive study

Last month
Bioregnum
R&D

Bio­gen’s top ex­ec­u­tive crew has a big cred­i­bil­i­ty is­sue. And they seem de­ter­mined to make it worse

Last month
People
Bioregnum

Piv­otal da­ta ce­ment use of In­cyte, No­var­tis' rux­oli­tinib in dif­fi­cult-to-treat graft-ver­sus-host dis­ease

Last month
R&D
Pharma

Still no ad­u­canum­ab fil­ing and an in-house gath­er­ing trig­gered a health dis­as­ter, but Bio­gen's CEO nev­er­the­less took home record pay

Last month
People

Cre­ative or un­eth­i­cal? Re­searchers’ Covid-19 Go­FundMe cam­paign spurs crit­ics

Last month
R&D
Coronavirus

Nat­ur­al killers are com­ing for Covid-19 and the ther­a­py, ex­perts say, could make things worse

Last month
R&D
Coronavirus

Who's do­ing deals in the midst of a crip­pling pan­dem­ic? Here are the top 10 play­ers for March

Last month
Deals

Biotech ex­ecs warn that the FDA is fum­bling their re­sponse to the Covid-19 open-door promise, de­lay­ing progress

Last month
Bioregnum
Regulatory

A small, ob­scure biotech just won big with their IPO. In this mar­ket. Are you kid­ding me?

2 months ago
Bioregnum
IPOs

FDA OKs a tri­al for a new Covid-19 ther­a­py af­ter an un­usu­al pub­lic­i­ty cam­paign touts its po­ten­tial — with help from Rudy Giu­liani

2 months ago
Bioregnum
R&D

The big C: The deal­mak­ers, dol­lars and dis­eases that have trans­formed the Chi­nese bio­phar­ma mar­ket

2 months ago
Venture
Deals

The glob­al top 50 bio­phar­ma com­pa­nies — End­points News style

2 months ago
R&D

'Dra­mat­ic times': How did an $8B surge in NIH grants over five years change re­search on the ground (if at all)?

2 months ago
Discovery
In Focus

The top 100 bio­phar­ma ven­ture in­vestors at the mega­bil­lions deal ta­ble

3 months ago
Venture

The top 10 bio­phar­ma pipeline blowups, set­backs and sna­fus for H2 2019

3 months ago
Bioregnum

Weak pipeline? Why, Sanofi ex­ecs are sud­den­ly over the moon about their prospects

3 months ago
Bioregnum
R&D

The pow­er of prece­dent: How a one-off de­ci­sion by Janet Wood­cock es­tab­lished an un­in­tend­ed fast path­way at the FDA — what will fol­low?

4 months ago
Bioregnum

The FDA un­veils a new reg­u­la­to­ry frame­work to speed along gene ther­a­pies, re­ward­ing the lead­ing play­ers

4 months ago
Bioregnum

Who knew? Der­mi­ra’s board kept watch as its stock price tracked Eli Lil­ly’s se­cret bid­ding on a $1.1B buy­out

4 months ago
Deals

#JPM20 ex­clu­sive: Olivi­er Brandi­court fol­lows the Big Phar­ma CEO path to pri­vate eq­ui­ty, join­ing Black­stone ahead of a mam­moth fund de­but

4 months ago
People
R&D
1234 Next page Last page